8-K current report · filed Nov 3, 2026

Revvity (RVTY) 8-K Current Report: November 3, 2026

Item EX-99.1Item EX-99.2Item 2.02Item 8.01RVTY overview

Short answer

Revvity (RVTY) filed an 8-K current report with the SEC on November 3, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events). Third-quarter results announced for period ended October 4, 2026.

Revvity 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Third-quarter results announced for period ended October 4, 2026
  • Full financial results and management commentary available in Exhibit 99.1
  • Results announcement provides updated operating performance information for Revvity investors

Item 8.01 · Other Events

  • Planned sale of substantially all China Immunodiagnostics assets for up to $200 million, subject to adjustments and closing conditions
  • Definitive agreement signed July 31, 2026, signaling portfolio reshaping and exit from China IDX operations
  • Management expects probable closing by end of 2027, making the transaction relevant to forward financial statements
  • Unaudited pro forma statements in Exhibit 99.2 show the anticipated balance-sheet and operating impact for investor review

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $729M, up from $699M, while pro forma organic growth reached 7%, indicating broad-based demand recovery
  • Adjusted EPS $1.38 versus $1.18, with adjusted operating margin expanding to 28.7% from 26.1%
  • Life Sciences led growth at 9% organic, while Diagnostics delivered 5% organic growth and margin improved to 29.9%
  • FY2026 guidance raised to approximately $2.86B revenue, 5% organic growth, and $5.40-$5.45 adjusted EPS
  • China IDX divestiture, representing approximately 6% of fiscal 2025 revenue, remains targeted for closing by end-2027

Item EX-99.2 · Exhibit EX-99.2

  • China IDX divestiture removes $120 million of potential consideration from pro forma assets, including transferred liabilities and excluding contingent consideration
  • Pro forma revenue reduced $164.6 million for 2025, while continuing-operations EPS falls from $2.07 to $1.63
  • Nine-month 2026 revenue declines $62.1 million, but operating income rises $15.1 million to $275.4 million after removing China IDX
  • 2025 pro forma net income declines $50.5 million, reflecting a $55 million probable disposition loss including tax impacts
  • Pro forma assets decrease $153.7 million to $11.34 billion, while equity decreases $117.8 million to $7.15 billion

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Revvity 8-K filings

Get the next RVTY 8-K as it lands

Follow RVTY for push alerts, or ask the research agent what this filing means.